The emergence of targeted agents (monoclonal antibodies, tyrosine kinase inhibitors, and antibody-drug conjugates) and immune checkpoint inhibitors has brought great improvement in prognosis for patients with advanced breast cancer. However, brain metastases complicate breast cancer treatment and impact the overall prognosis. In addition, the potential cognitive decline associated with whole brain radiation therapy (WBRT) makes it a less desirable treatment. Recent studies have demonstrated the feasibility of receiving systemic therapy prior to standard radiotherapy in patients with metastatic breast cancer and brain metastases. Therefore, the identification of new drug targets, mechanisms of drug resistance, as well as advances on new drug delivery systems are crucial for the development of new treatments for these patients.
In this Research Topic, we aim to publish articles focusing on recent advances in the treatments for patients with advanced breast cancer and brain metastases. We will focus on novel agents and new insights into the known regimens, including new delivery systems. We will also focus on biomarkers for efficacy and mechanisms of drug resistance in advanced breast cancer with brain metastases. Any Original Research and Review focusing on the following aspects are welcome:
• Novel agents or regimens for advanced breast cancer with the potential to treat brain metastases, including chemotherapy, targeted therapy, and immunotherapy
• Local radiotherapy for breast cancer metastatic to the brain
• Predictive and prognostic biomarkers for the treatment in breast cancer metastatic to the brain
• Early diagnosis and management of brain metastases from breast cancer
• Mechanisms of drug resistance in breast cancer metastatic to the brain
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
The emergence of targeted agents (monoclonal antibodies, tyrosine kinase inhibitors, and antibody-drug conjugates) and immune checkpoint inhibitors has brought great improvement in prognosis for patients with advanced breast cancer. However, brain metastases complicate breast cancer treatment and impact the overall prognosis. In addition, the potential cognitive decline associated with whole brain radiation therapy (WBRT) makes it a less desirable treatment. Recent studies have demonstrated the feasibility of receiving systemic therapy prior to standard radiotherapy in patients with metastatic breast cancer and brain metastases. Therefore, the identification of new drug targets, mechanisms of drug resistance, as well as advances on new drug delivery systems are crucial for the development of new treatments for these patients.
In this Research Topic, we aim to publish articles focusing on recent advances in the treatments for patients with advanced breast cancer and brain metastases. We will focus on novel agents and new insights into the known regimens, including new delivery systems. We will also focus on biomarkers for efficacy and mechanisms of drug resistance in advanced breast cancer with brain metastases. Any Original Research and Review focusing on the following aspects are welcome:
• Novel agents or regimens for advanced breast cancer with the potential to treat brain metastases, including chemotherapy, targeted therapy, and immunotherapy
• Local radiotherapy for breast cancer metastatic to the brain
• Predictive and prognostic biomarkers for the treatment in breast cancer metastatic to the brain
• Early diagnosis and management of brain metastases from breast cancer
• Mechanisms of drug resistance in breast cancer metastatic to the brain
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
